CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.
about
Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell NeoplasmsAntibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in miceSmall molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasiasRecent advances in antimultiple myeloma drug development.Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration.Targeted therapies for adrenocortical carcinoma: IGF and beyond.FGFR2 promotes breast tumorigenicity through maintenance of breast tumor-initiating cells.Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11).Evaluation of tyrosine receptor kinases in the interactions of head and neck squamous cell carcinoma cells and fibroblasts.Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.UCHL1 is a biomarker of aggressive multiple myeloma required for disease progressionMaintenance therapy in multiple myeloma.Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials.From the bench to the bedside: emerging new treatments in multiple myeloma.The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancerMultiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition.Targeting mutant fibroblast growth factor receptors in cancer.Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy.Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models.Understanding the molecular biology of myeloma and its therapeutic implications.Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation.The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies.A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells.Molecular therapeutic strategies for FGFR3 gene-related skeletal dysplasia.The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.Clinical and biological features of t(4;14) multiple myeloma: a prospective study
P2860
Q26795594-72F71B2D-7889-49F3-9AB7-CA4D5A2546A4Q27654979-C3C43314-94C2-49FB-AB79-E4ED07859C04Q27851612-9EACC6EE-B4AD-4919-811A-7FA1C1ED332CQ28252023-09F419FD-70BC-4617-9FC8-63C513E032C6Q33416297-5B833307-C0E2-48EA-9703-338CC21517CAQ33783047-98C0033B-107C-47A1-A817-7D3B3CB4557AQ34101433-87D6B203-FFEA-409E-A2A8-C923A5A51781Q34542012-FB306EA4-8630-4133-AE4F-7E441C9E9D0EQ34704781-46EB54D2-5FF3-410A-B534-5E5246C989FAQ35018563-A1B30D1A-A97D-47DF-94D3-84C2A7223776Q36395148-750CEB26-D4E7-467D-878A-8B1B4FAE536DQ36555872-E74F51B2-E28E-4E6C-9392-0717B9B8E3BCQ36562144-67B5D957-2AD0-49D8-B35D-1C0A24D48470Q36754178-C361337C-1CD0-4D40-B1F5-575A8BC10A05Q36844954-44AB82C9-DE57-4A96-A420-119D65244E93Q37028598-8988D0C5-E79B-4E12-B041-6325BFB8089EQ37061044-BBAC3FA1-B316-49AC-8DEE-BAE052715593Q37389768-9C095F7E-3AEF-4736-B7A1-4A10D947ED80Q37415946-BC2A662A-E6F8-4DB3-A92E-2FD6FBD1BC42Q37849013-7934D7B2-4403-4D9C-9885-8EA02CBC8204Q37849781-C8604F95-AACE-4E5A-B0F8-D944F07D82CAQ38056889-77CA89C7-0599-45AD-B187-FD9A43C8B445Q38065305-612E93A6-58DB-41CE-B802-9D3958A05FCEQ38268782-1947CBB8-BA39-4F06-B544-BE3730745180Q42155683-14C63991-9119-426F-B371-95C1AAA64988Q42734250-7A865C4E-ACEB-436A-9600-F2B9E3170DBFQ47612372-0A2EA64A-DB2B-428C-912F-055071BA250DQ50085302-446F5FD4-E1D4-43FB-9AD2-A4E0D2DB2ABBQ57217664-27607B2A-46DC-4466-8E67-39437ACED1A5
P2860
CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
CHIR-258 is efficacious in a n ...... ultiple myeloma model in mice.
@en
type
label
CHIR-258 is efficacious in a n ...... ultiple myeloma model in mice.
@en
prefLabel
CHIR-258 is efficacious in a n ...... ultiple myeloma model in mice.
@en
P2093
P1476
CHIR-258 is efficacious in a n ...... ultiple myeloma model in mice.
@en
P2093
Bahija Jallal
Carla C Heise
Debbie E Swinarski
Dirk B Mendel
Evelyn N Garrett
Katherine G Rendahl
Millicent G Embry
Nancy K Pryer
Paul W Hollenbach
Tinya J Abrams
P304
P356
10.1158/1078-0432.CCR-06-0957
P407
P577
2006-08-01T00:00:00Z